BridgeBio Oncology Therapeutics Inc
BBOT
Company Profile
Business description
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Contact
256 East Grand Avenue
Suite 104
South San FranciscoCA94080
USAT: +1 650 405-4770
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
106
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,882.60 | 20.50 | -0.23% |
| CAC 40 | 8,258.26 | 142.51 | 1.76% |
| DAX 40 | 25,389.10 | 500.54 | 2.01% |
| Dow JONES (US) | 50,579.70 | 294.04 | 0.58% |
| FTSE 100 | 10,466.26 | 22.79 | 0.22% |
| HKSE | 25,674.90 | 68.87 | 0.27% |
| NASDAQ | 26,343.97 | 50.87 | 0.19% |
| Nikkei 225 | 64,996.09 | 162.10 | -0.25% |
| NZX 50 Index | 13,069.74 | 99.46 | 0.77% |
| S&P 500 | 7,473.47 | 27.75 | 0.37% |
| S&P/ASX 200 | 8,657.80 | 18.80 | -0.22% |
| SSE Composite Index | 4,148.23 | 4.34 | -0.10% |